HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products - Top-Institutions - MDSpire

HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products

  • By

  • Assistant Secretary for Public Affairs (ASPA)

  • July 1, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine and The Johns Hopkins Hospital
    Johns Hopkins University School of Medicine and The Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Pharmacology
    • Behavioral Science

  • #2

    University of Florida
    University of Florida

    Gainesville, Florida

    Key Differentiators

    • Pharmacology
    • Medicinal Chemistry

Original Source(s)

HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products

  • by Assistant Secretary for Public Affairs (ASPA)

  • July 1, 2026

Related Content

Additive impulsivity and emotion dysregulation in adolescents with comorbid bipolar and substance use disorder: a cross-sectional factorial study

Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder

Trump Bought Tobacco Stocks and Raked In Industry Donations as FDA Eased Standards

Trump’s tobacco investments and industry donations coincided with FDA moves that benefited major nicotine companies.